Patients in the treatment group had shorter follow-up duration, more comorbidities, including diabetes mellitus, dyslipidemia, hypertension, and chronic kidney disease, and took more medications (e.g. aspirin, P2Y12 inhibitors, and angiotensin converting enzyme inhibitors/angiotensin receptor blockers) than patients in the non-treatment group before propensity score matching. Here, ACE is linked to metabolic syndrome.